Mandolin is a San Francisco-based healthcare technology company that builds an AI-enabled workflow automation platform for the administrative tasks involved in specialty drug management.[1][2][3] It serves infusion centers, specialty drug clinics, hospitals, and healthcare providers by automating complex back-office processes like intake, benefits verification, prior authorizations, patient cost estimation, claims management, and appeals—without requiring APIs or EHR integrations.[1][2][3] The platform solves the problem of manual, labor-intensive workflows that delay patient access, increase denials, and hinder revenue in a market where specialty drugs drove 71.1% of total drug spending in 2021 despite only 6.2% of prescriptions.[1] Launched in January (year unspecified in sources), Mandolin is deployed in over 700 clinical locations and recently raised $40M from investors including Maverick, SignalFire, SV Angel, Greylock Partners, Jerry Yang, and Guillermo Rauch to expand engineering and customer implementation.[1]
Mandolin was cofounded by Will Yin, who serves as CEO, though specific founding year and additional cofounder details are not detailed in available sources.[1] The idea emerged to address the administrative bottlenecks in specialty drug administration, leveraging AI to mimic back-office specialists in navigating payer portals, reading faxes, making calls, and reasoning with unstructured data like referral forms and clinical notes.[3][2] Early traction came quickly post-launch in January, with deployment across more than 700 clinical locations, enabling clinics to scale without added staff while accelerating authorizations and reducing denials.[1][3] The $40M funding round marks a pivotal moment, fueling team growth to serve sophisticated customers in this high-stakes sector.[1]
Mandolin stands out in healthcare automation through these key strengths:
(Note: A separate entity at mandolin.live offers concert streaming, unrelated to this healthcare firm.[4])
Mandolin rides the explosive growth of specialty drugs, which surged from 21.7% to 71.1% of total spending (2012-2021), amid rising demand for biologics, oncology, and rare disease treatments.[1] Timing is ideal as AI advancements enable "precision automation" for fragmented payer systems and unstructured healthcare data, reducing administrative burdens that block access in a $100B+ market.[2][3] Favorable forces include payer complexity, staff shortages in clinics, and regulatory pushes for transparency (e.g., No Surprises Act), positioning Mandolin against competitors like SamaCare, Serve You Rx, and Waltz Health.[1] It influences the ecosystem by enabling providers to prioritize care over paperwork, boosting AI adoption in revenue cycle management and setting a model for integration-free tools in digital health.
Mandolin's $40M raise positions it to dominate AI-driven specialty drug admin, with plans for elite engineering hires to deepen platform capabilities and customer wins.[1] Upcoming trends like multimodal AI (for faxes/notes), real-time payer APIs, and value-based care will amplify its edge, potentially expanding to adjacent areas like gene therapies. Its influence may grow by standardizing compliant automation, unlocking revenue for thousands more clinics and reshaping how providers handle high-margin drugs—turning back-office drudgery into a scalable advantage, much like its platform does today.
Mandolin has raised $57.0M in total across 3 funding rounds.
Mandolin's investors include 645 Ventures, CRV, Fika Ventures, Foundry Group, Goat Capital, Greylock, High Alpha, Index Ventures, Khosla Ventures, Kleiner Perkins, Maverick Capital, Saga.
Mandolin has raised $57.0M across 3 funding rounds. Most recently, it raised $40.0M Series A in June 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2025 | $40.0M Series A | 645 Ventures, CRV, Fika Ventures, Foundry Group, Goat Capital, Greylock, High Alpha, Index Ventures, Khosla Ventures, Kleiner Perkins, Maverick Capital, Saga, Sequoia Capital, SignalFire, The Community Fund, Thrive Capital, Underscore VC, Balaji Srinivasan, Ding Zhou, Guillermo Rauch, Karim Atiyeh, Marc Benioff, Michael Stoppelman, Mike Liu, Scott Belsky, Steve King, Varsha Rao | |
| Jun 1, 2021 | $12.0M Series A | 645 Ventures, AlleyCorp, Rexhep Dollaku, Foundry Group, Great Oaks Venture Capital, High Alpha, Pareto Holdings, Predictive VC, Tribe Capital | |
| Oct 1, 2020 | $5.0M Seed | Rexhep Dollaku, Define Ventures, Gigascale Capital, High Alpha, Jetstream, Khosla Ventures, Kleiner Perkins, Obvious Ventures, William Miller |
